Biotechnology
PharmAbcine to Present at H.C Wainwright Ophthalmology Virtual Conference
DAEJEON, South Korea, July 26, 2021 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next generation antibody therapeutics, announced today that the company is invited to deliver a video presentation at H.C Wainwright Ophthalmolo...
Deep Longevity Releases an AI-based Predictor of COVID Time-To-Death
HONG KONG, July 26, 2021 /PRNewswire/ -- Endurance RP Limited's ("Endurance Longevity" or the "Company" and together with its subsidiaries, the "Group"; stock code: 0575.HK) wholly-owned subsidiary Deep Longevity, Inc, a leading provider of deep biomarkers of aging and longevity is pleased to ann...
Hummingbird Bioscience Appoints Renowned Scientist and Medical Oncologist Dr. Thomas J. Lynch to its Board of Directors
HOUSTON and SINGAPORE, July 26, 2021 /PRNewswire/ -- Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets, today announced that internationally renowned scientist and medical oncologist, Dr. Thomas J Lynch, Jr,...
Laekna Therapeutics will present two clinical study results in ESMO 2021
SHANGHAI and WARREN, N.J., July 26, 2021 /PRNewswire/ -- Laekna Therapeutics, an emerging innovative pharma company based inChina's "Zhangjiang Pharma Valley" andNew Jersey in the U.S. and focused on developing new groundbreaking innovative therapies to treat cancer and liver diseases, announced ...
Antengene and Its Partners Publish Preclinical Data Demonstrating the Encouraging Activity of Selinexor in the Prevention and Treatment of SARS-CoV-2 Infections
SHANGHAI and HONG KONG, July 26, 2021 /PRNewswire/ -- In June 2021, results from a preclinical study jointly conducted by Antengene, American biopharmaceutical company Karyopharm Therapeutics andUniversity of Georgia College of Veterinary Medicine has been published in a paper titled "selinexor, ...
Innovent Announces the First Patient Dosed in the Phase 1 Study of IBI321 (Anti-PD-1/TIGIT Bispecific Antibody) in Patients with Advanced Malignant Tumors
SAN FRANCISCO and SUZHOU, China, July 25, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseas...
FDA Provides Necessary Guidance For BioVaxys To Begin Preparation Of Ind For Phase I/II Clinical Trials Of CoviDTH
VANCOUVER, British Columbia, July 22, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA:5LB) (OTCQB: BVAXF)("BioVaxys"), is pleased to announce today that the US Food and Drug Administration ("FDA") has provided its official Written Response to the Company's request for a Pre-IN...
Intas Enters into an Exclusive License Agreement with Meiji and Dong-A ST to commercialize DMB-3115 (Proposed Biosimilar to Ustekinumab)
Intas Pharmaceuticals Ltd continues to pledge their commitment to increasing access to high quality medicines by entering into an exclusive license agreement AHMEDABAD, India, July 22, 2021 /PRNewswire/ -- Intas Pharmaceuticals Ltd continues to pledge their commitment to increasing access to high...
Menarini Asia-Pacific strengthens Men's Health portfolio in China with acquisition of Cialis(R) (Tadalafil) from Lilly
* Acquisition of Cialis® in the People's Republic of China to bolster Menarini's Men's Health portfolio and drive multichannel coverage * This is a significant milestone for Menarini Asia operations as it commemorates its 10th anniversary of being established in 13 major healthcare markets in...
Antengene Announces The Approval by Human Research Ethics Committee in Australia and to Start the Phase 1 Trial of ATG-101 (the first PD-L1/4-1BB bispecific antibody) in Solid Tumors and Non-Hodgkin Lymphoma
SHANGHAI and HONG KONG, July 22, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncol...
AnchorDx's Non-invasive Bladder Cancer Early Detection Test, UriFind, Earns "Breakthrough Device Designation" from FDA
GUANGZHOU, China, July 21, 2021 /PRNewswire/ -- AnchorDx, a world-leading developer of cancer screening and early detection solutions, onJuly 13, 2021, was awarded aBreakthrough Device Designation ("BTD")[1] by the US Food and Drug Administration (FDA) for UriFind (or "the Test"), an early detect...
Hyundai Mobis develops the world's first 'brainwaves' based ADAS technology
SEOUL, South Korea, July 21, 2021 /PRNewswire/ -- After 3 years of R&D, Hyundai Mobis (KRX: 012330) finally succeeded in developing M.Brain, a new healthcare technology based on brainwave measurement. This achievement is receiving great attention for applying this brainwave measurement technology...
Ascentage Pharma's MDM2-p53 Inhibitor APG-115 (Alrizomadlin) Granted an Orphan Drug Designation by the FDA for the Treatment of Stage IIB-IV Melanoma, Marking the Twelfth Obtained by the Company
SUZHOU, China and ROCKVILLE, Md., July 21, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the US Food and Drug Administration (F...
Clarivate Introduces Cortellis Supply Chain Network™, a Revolutionary Digital Partnering Solution
LONDON, July 21, 2021 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced the launch of theCortellis Supply Chain Network™, a part of the Cortellis suite of life science intelligence soluti...
Synthetic Biology Startup Allozymes Raises US $5 Million Seed Round to Deliver Sustainable, Scalable Manufacturing of Natural Ingredients
* Responsible consumers and companies are increasingly unwilling to tolerate the significant environmental impacts associated with natural ingredients sourcing. * The startup, co-founded by scientist-entrepreneurs, Peyman Salehian, PhD and Akbar Vahidi, PhD, employs a unique technology platfor...
Direct Biologics Announces FDA Approval for Proceeding With Second ExoFlo IND for Post-Acute COVID-19 Syndrome and Chronic Post-COVID-19 Syndrome
Extracellular Vesicle Isolate Product ExoFlo Shows Strong Potential to Treat COVID-19, Post-Acute COVID-19 Syndrome, and Chronic Post-COVID-19 Syndrome; 60-patient trial to be conducted nationally at ambulatory infusion sites AUSTIN, Texas, July 21, 2021 /PRNewswire/ -- Direct Biologics, a marke...
ExoFlo™ From Direct Biologics Fulfills Urgent Medical Need in COVID-19 Treatment
Medical professionals report dramatic and consistent success in treating patients gravely ill with COVID-19-associated Acute Respiratory Distress Syndrome (ARDS) AUSTIN, Texas, July 21, 2021 /PRNewswire/ -- As intensive care units across the country fill to capacity, hospital beds are in dangero...
OriCiro Announces ¥1 Billion Series B Financing to Advance Cell-Free DNA Technology for Innovative Therapeutics and Synthetic Biology
TOKYO, July 20, 2021 /PRNewswire/ -- OriCiro Genomics, a pioneer in cell-free synthesis and amplification of genome-scale large DNA for advanced therapy and synthetic biology, today announced that it has raised ¥800 million in Series B financing led by TheUniversity of Tokyo Edge Capital Partners...
Terumo and UMCU strengthen their partnership to develop solutions in Interventional Oncology
LEUVEN, Belgium, July 20, 2021 /PRNewswire/ -- Terumo Europe and University Medical Center Utrecht (UMC Utrecht) announced today that they signed a Memorandum of Understanding (MoU) to recognize the longstanding partnership in the field of oncology. In the past years, both parties have successful...
Harbour BioMed Appoints Yingying Chen, PhD, as Chief Financial Officer
CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, July 20, 2021 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX:02142) announced the appointment of Dr. Yingying Chen as Chief Financial Officer (CFO). Dr. Chen will be responsible for leading the overall management of Finance & Investor Re...
Week's Top Stories
Most Reposted
Visa partners with Laufey to spread the magic of travel in Asia Pacific; to be Official Payment Partner for Laufey: A Matter of Time Tour
[Picked up by 309 media titles]
2026-03-04 12:35SMU and Fudan Launch Region's First Tech-Focused DBA
[Picked up by 300 media titles]
2026-03-02 09:15Klook's Spring Readiness Index shows how Asia's travelers are preparing for spring travel across Japan, South Korea, and Mainland China
[Picked up by 291 media titles]
2026-03-03 15:49Infobip is set to launch AgentOS to orchestrate autonomous AI-driven customer journeys at scale
[Picked up by 290 media titles]
2026-03-02 09:00COL and NASDAQ-Listed BeLive Holdings Unveil World's First "Microdrama in a Box" in Headline Hong Kong FILMART 2026 Launch
[Picked up by 287 media titles]
2026-03-05 17:14